Aptevo Therapeutics Files 8-K: Material Agreement & Security Holder Changes

TL;DR

APVO filed an 8-K on Nov 1, 2024, for a material agreement and changes to security holder rights.

AI Summary

Aptevo Therapeutics Inc. announced on November 1, 2024, that it entered into a material definitive agreement. The company also reported modifications to the rights of its security holders and filed financial statements and exhibits as part of this 8-K filing. Specific details regarding the agreement and modifications were not provided in the initial filing summary.

Why It Matters

This filing indicates significant corporate actions by Aptevo Therapeutics, potentially impacting its business operations, financial structure, and shareholder rights.

Risk Assessment

Risk Level: medium — Material definitive agreements and modifications to security holder rights can introduce significant business and financial risks.

Key Players & Entities

• Aptevo Therapeutics Inc. (company) — Registrant
• November 01, 2024 (date) — Date of earliest event reported
• 206-838-0500 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value APVO The Nasdaq Stock Mar
• $0 — articipating Preferred Stock, par value $0.001, of the Company. The Amendment ex
• $70 — ted language in the Rights Agreement to $70 per one one-thousandth of a Preferred S

Filing Documents

• apvo-20241101.htm (8-K) — 42KB
• apvo-ex4_1.htm (EX-4.1) — 33KB
• 0000950170-24-120188.txt ( ) — 194KB
• apvo-20241101.xsd (EX-101.SCH) — 25KB
• apvo-20241101_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On November 1, 2024, Aptevo Therapeutics Inc. (the "Company") entered into Amendment No. 4 (the "Amendment") to the Rights Agreement, dated as of November 8, 2020, between the Company and Broadridge Corporate Issuer Solutions, Inc., as Rights Agent, as amended (the "Rights Agreement"). The Rights Agreement pertains to those certain contingent rights to purchase one one-thousandth of a share of Series A Junior Participating Preferred Stock, par value $0.001, of the Company. The Amendment extends the definition of "Final Expiration Date" (as defined in the Rights Agreement) and certain related language in the Rights Agreement to October 31, 2025. The Amendment also changes the definition of "Purchase Price" (as defined in the Rights Agreement) and certain related language in the Rights Agreement to $70 per one one-thousandth of a Preferred Share. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amendment, a copy of which is attached as Exhibit 4.1 to this Current Report on Form 8-K and incorporated herein by reference.

03 Material Modification to Rights of Security Holders

Item 3.03 Material Modification to Rights of Security Holders. The information set forth under "Item 1.01 Entry into a Material Definitive Agreement" of this Current Report on Form 8-K is incorporated into this Item 3.03 by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Number Description 4.1 Amendment No. 4 to Rights Agreement, dated as of November 1, 2024, between the Company and Broadridge Corporate Issuer Solution, Inc., as Rights Agent 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. APTEVO THERAPEUTICS INC. Date: November 1, 2024 By: /s/ Marvin L. White Marvin L. White President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR